Belinostat (PXD101): Pan-HDAC Inhibitor for Epigenetic Cancer Research

Executive Summary: Belinostat (PXD101) is a hydroxamate-type histone deacetylase inhibitor (HDACi) with potent pan-HDAC activity (IC50 = 27 nM in HeLa cell extracts; see product page). It modulates acetylation of histones H3 and H4, leading to chromatin relaxation and altered gene expression. In vitro, it inhibits proliferation across multiple tumor cell lines—most notably urothelial and prostate cancer—with IC50 values between 0.5–10 μM. In vivo, intraperitoneal administration at 100 mg/kg reduces bladder tumor burden in transgenic mouse models without significant toxicity. APExBIO supplies Belinostat as a solid (C15H14N2O4S, MW = 318.35), best stored at -20°C. These properties establish Belinostat as a validated reference for epigenetic and translational oncology research (Schwartz, 2022).

Biological Rationale

Epigenetic regulation via histone acetylation is critical for gene expression control in both healthy and cancerous cells. Histone deacetylases (HDACs) remove acetyl groups from lysine residues on histones, promoting chromatin condensation and transcriptional repression. Dysregulation of HDAC activity is associated with oncogenic transformation and tumor progression, especially in urothelial and prostate cancers (Schwartz, 2022). Targeting HDACs with inhibitors like Belinostat (PXD101) can restore normal acetylation patterns, reactivate silenced tumor suppressor genes, and inhibit proliferation of cancer cells.

Mechanism of Action of Belinostat (PXD101)

Belinostat is a hydroxamate-type small molecule that chelates the zinc ion in the catalytic site of HDAC enzymes. It inhibits multiple HDAC isoforms (pan-HDAC activity), with an IC50 of 27 nM reported in HeLa cell extracts. Upon HDAC inhibition, Belinostat increases acetylation of histones H3 and H4, leading to a relaxed chromatin structure. This chromatin remodeling results in altered transcription of genes involved in cell cycle regulation, apoptosis, and differentiation. In tumor cells, Belinostat induces cell cycle arrest (increased G0-G1 phase, decreased S phase) and apoptosis, thereby suppressing cancer cell growth (Schwartz, 2022).

Evidence & Benchmarks

• Belinostat demonstrates pan-HDAC inhibitory activity in HeLa extracts with an IC50 of 27 nM (APExBIO).
• Inhibition of proliferation observed in multiple tumor cell lines, including bladder (5637, T24, J82, RT4) and prostate cancer cells (IC50: 0.5–10 μM, depending on the model; conditions: 24–72 h treatment, standard culture media) (Schwartz, 2022).
• Induces cell cycle arrest by decreasing the proportion of S phase cells and increasing G0-G1 phase cells in urothelial carcinoma models (Schwartz, 2022).
• In vivo administration (i.p., 100 mg/kg, 5 days/week, 3 weeks) in UPII-Ha-ras transgenic mice led to reduced bladder tumor weight and inhibited disease progression, with no significant toxicity observed (Schwartz, 2022).
• Belinostat is insoluble in water but soluble in DMSO (≥15.92 mg/mL) and ethanol (≥44.1 mg/mL, with ultrasonication; room temperature) (APExBIO).

For additional integrative insights on Belinostat’s in vitro cancer research applications, see this article, which provides a broader overview but does not elaborate on solubility or storage parameters as in the current dossier.

For a mechanistic focus on pan-HDAC inhibition and next-generation epigenetic workflows, refer to this guide, which complements this article by detailing troubleshooting and application design beyond the product’s primary benchmarks.

Applications, Limits & Misconceptions

Belinostat (PXD101) serves as a reference HDAC inhibitor for investigating mechanisms of cell cycle arrest, apoptosis, and gene expression modulation in cancer models. Its low-nanomolar potency and broad-spectrum activity make it suitable for:

• Epigenetic drug screening in urothelial and prostate cancer cell lines
• Preclinical in vivo efficacy studies using transgenic mouse models of bladder cancer
• Mechanistic dissection of HDAC-dependent gene regulation

However, the following boundaries are critical:

Common Pitfalls or Misconceptions

• Belinostat is not effective as a selective HDAC isoform inhibitor; it is pan-reactive.
• Its cytotoxicity in non-cancerous cells is not well characterized and may limit translational relevance outside oncology.
• Solubility in aqueous buffers is poor; DMSO or ethanol is required for stock preparation.
• Belinostat solutions are not stable for long-term storage; fresh preparation is recommended for each experiment.
• In vivo efficacy and safety data are currently limited to specific mouse models; generalization to other species and tumor types requires caution.

See this related article for further discussion on pan-HDAC inhibition and how this review updates the field by clarifying application limits and formulation stability.

Workflow Integration & Parameters

For in vitro work, dissolve Belinostat in DMSO (≥15.92 mg/mL) or ethanol (≥44.1 mg/mL, with ultrasonic treatment). Store solid at -20°C; use solutions promptly. Proliferation assays (e.g., MTT, CellTiter-Glo) should assess response in the 0.5–10 μM concentration range, using 24–72 h incubation. For in vivo studies, intraperitoneal dosing at 100 mg/kg (5 days per week, up to 3 weeks) is validated in UPII-Ha-ras mouse models. Monitor for toxicity and tumor endpoints as described in Schwartz, 2022. For detailed experimental workflows, see this article, which outlines strategic integration of pan-HDAC inhibitors, but the present summary provides more explicit solubility and dosing guidance for A4096 users.

Conclusion & Outlook

Belinostat (PXD101) from APExBIO is a robust, well-characterized pan-HDAC inhibitor suitable for mechanistic and translational research in epigenetic oncology. Its low-nanomolar in vitro potency, reproducible in vivo activity, and well-understood mechanism make it a reference tool for dissecting HDAC-driven cancer biology. Continued research is needed to expand its utility beyond bladder and prostate cancer models, define long-term safety, and explore combinatorial regimens. For detailed product information, including physico-chemical properties and ordering, visit the APExBIO Belinostat (PXD101) page.